HIPEC + FLOT vs. FLOT Alone in Patients With Gastric Cancer and GEJ (PREVENT) (PREVENT)
Preventive HIPEC in Combination With Perioperative FLOT Versus FLOT Alone for Resectable Diffuse Type Gastric and Gastroesophageal Junction Type II/III Adenocarcinoma - The Phase III PREVENT Trial of the AIO /CAOGI /ACO
Sponsor: Deutsche Krebshilfe e.V., Bonn (Germany)
Listed as NCT04447352, this PHASE3 trial focuses on Gastric Cancer and Gastroesophageal Junction Adenocarcinoma and remains actively recruiting participants. Sponsored by Deutsche Krebshilfe e.V., Bonn (Germany), it has been updated 10 times since 2020, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
10 versions recorded-
Dec 2024 — Present [monthly]
Recruiting PHASE3
-
Sep 2024 — Dec 2024 [monthly]
Recruiting PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Recruiting PHASE3
-
Dec 2023 — Jul 2024 [monthly]
Recruiting PHASE3
-
Sep 2022 — Dec 2023 [monthly]
Recruiting PHASE3
▶ Show 5 earlier versions
-
Sep 2021 — Sep 2022 [monthly]
Recruiting PHASE3
-
Jan 2021 — Sep 2021 [monthly]
Recruiting PHASE3
Status: Not Yet Recruiting → Recruiting
-
Oct 2020 — Jan 2021 [monthly]
Not Yet Recruiting PHASE3
-
Aug 2020 — Oct 2020 [monthly]
Not Yet Recruiting PHASE3
-
Jul 2020 — Aug 2020 [monthly]
Not Yet Recruiting PHASE3
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Deutsche Krebshilfe e.V., Bonn (Germany)
- Krankenhaus Nordwest
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Aachen, Germany , Dresden, Germany , Frankfurt, Germany , Halle, Germany , Leipzig, Germany , Ludwigsburg, Germany , Lübeck, Germany , Magdeburg, Germany , München, Germany , Münster, Germany and 5 more locations